Dudediligence.

Dianthus Therapeutics, Inc

DNTHNASDAQ · Pharmaceutical Preparations
Write an idea

Insiders

Last 12 months

Sales planned on beside the trades reported on , and whether each names a .

Planned ·

$63.4M

18 notices · 682,016 sh

Mar 4 to Oct 4

Reported ·

$41.9M

33 sales · 0 buys

Oct 2025 to Jun 2026

The two figures cover different periods.

All 33 reported sales carry the 10b5-1 box. Together they are 1.12% of the shares on issue.

PLANNED · FORM 144Mar 4 to Oct 4REPORTED · FORM 4Oct 2025 to Jun 2026N2025DJ2026FMAMJJASO2026-09-17: EDWARD CARR, Form 1442026-09-01: SIMRAT RANDHAWA, Form 1442026-08-10: Read Simon, Form 1442026-08-10: ADAM VENESS, Form 1442026-08-10: ANNE M MCGEORGE, Form 1442026-08-07: MARINO GARCIA, Form 1442026-08-07: ADAM VENESS, Form 1442026-08-07: MARINO GARCIA, Form 1442026-07-09: RYAN SAVITZ, Form 1442026-06-17: ADAM M VENESS, Form 1442026-06-01: SIMRAT RANDHAWA, Form 1442026-04-09: RYAN SAVITZ, Form 1442026-03-31: RYAN SAVITZ, Form 1442026-03-31: PAULA C SOTEROPOULOS, Form 1442026-03-24: PAULA C SOTEROPOULOS, Form 1442026-03-12: MARINO GARCIA, Form 1442026-03-12: SIMRAT RANDHAWA, Form 1442026-03-12: EDWARD CARR, Form 1442025-11-13: Randhawa Simrat, sold2025-12-04: Savitz Ryan, sold2026-03-12: CARR EDWARD, sold2026-03-12: Garcia Marino, sold2026-03-12: Randhawa Simrat, sold2026-03-24: Soteropoulos Paula, sold2026-03-31: Soteropoulos Paula, sold2026-03-31: Savitz Ryan, sold2026-04-09: Savitz Ryan, sold2026-05-08: Soteropoulos Paula, sold2026-06-01: Randhawa Simrat, sold2026-06-17: Veness Adam M, sold
under a no plan named▼ salesize is dollars

Form 144 notices, newest first

2026-09-17EDWARD CARR, CHIEF ACCOUNTING OFFICER$2,049,800
20,000 shplan 2026-06-18Form 4s on file end Jun 23144 ↗
2026-09-01SIMRAT RANDHAWA, EVP, Head of R&D$2,442,126
23,124 shplan 2025-08-14Form 4s on file end Jun 23144 ↗
2026-08-10Read Simon, Officer$624,375
5,550 shplan 2026-05-08Form 4s on file end Jun 23144 ↗
2026-08-10ADAM VENESS, SVP, General Counsel and Sec.$1,760,910
16,167 shplan 2026-03-18Form 4s on file end Jun 23144 ↗
2026-08-10ANNE M MCGEORGE, Director$844,130
7,750 shplan 2026-05-11Form 4s on file end Jun 23144 ↗
2026-08-07MARINO GARCIA, CEO AND PRESIDENT$4,396,800
40,000 shplan 2026-05-08Form 4s on file end Jun 23144 ↗
2026-08-07ADAM VENESS, SVP, General Counsel and Sec.$421,323
3,833 shplan 2026-03-18Form 4s on file end Jun 23144 ↗
2026-08-07MARINO GARCIA, CEO AND PRESIDENT$13.6M
126,000 shno plan dateForm 4s on file end Jun 23144 ↗
2026-07-09RYAN SAVITZ, EVP, CFO & CBO$3,064,589
31,249 shplan 2025-12-30Form 4s on file end Jun 23144 ↗
2026-06-17ADAM M VENESS, SVP, General Counsel and Sec.$2,366,400
30,000 shplan 2026-03-18144 ↗
Form 4, 2026-06-18: sold 30,000 at $80.80 Form 4 ↗
2026-06-01SIMRAT RANDHAWA, EVP, Head of R&D$2,467,555
26,530 shplan 2025-08-14144 ↗
Form 4, 2026-06-02: sold 26,530 at $90.62 Form 4 ↗
2026-04-09RYAN SAVITZ, EVP, CFO & CBO$719,436
8,224 shplan 2025-12-30144 ↗
Form 4, 2026-04-10: sold 8,224 at $89.84 Form 4 ↗
2026-03-31RYAN SAVITZ, EVP, CFO & CBO$9,086,458
114,367 shplan 2025-12-30144 ↗
Form 4, 2026-04-01: sold 114,367 at $83.00 Form 4 ↗
2026-03-31PAULA C SOTEROPOULOS, Director$95,181
1,198 shplan 2025-12-23144 ↗
Form 4, 2026-04-01: sold 599 at $80.11 Form 4 ↗
2026-03-24PAULA C SOTEROPOULOS, Director$2,188,756
27,594 shplan 2025-12-23144 ↗
Form 4, 2026-03-26: sold 27,594 at $78.05 Form 4 ↗
2026-03-12MARINO GARCIA, CEO AND PRESIDENT$10.6M
122,918 shplan 2025-11-17144 ↗
Form 4, 2026-03-13: sold 122,918 at $81.49 Form 4 ↗
2026-03-12SIMRAT RANDHAWA, EVP, Head of R&D$2,903,967
33,830 shplan 2025-08-14144 ↗
Form 4, 2026-03-13: sold 33,830 at $81.48 Form 4 ↗
2026-03-12EDWARD CARR, CHIEF ACCOUNTING OFFICER$3,749,663
43,682 shplan 2025-12-11144 ↗
Form 4, 2026-03-13: sold 43,682 at $81.49 Form 4 ↗